UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042.

Recce Pharma announces positive clinical data from phase II trial of RECCE 327 gel in acute bacterial skin & skin structure infections: Sydney Friday, February 21, 2025, 16:00 Hrs ...

Microba Life Sciences (ASX:MAP), which has technology for measuring the gut microbiome, has a strategic partnership deal with pathology and radiology giant Sonic Healthcare (ASX:SHL), which acquired ...

Bausch & Lomb is one of the largest vision care companies in the US. Bausch spun off from its former parent company, Bausch Health, in 2022 and it now operates in three segments: vision care, surgical ...

The first of what is hoped to be an annual study of the region's sector is positive but lack of funding, laboratory space and ...

Australia’s Recce Pharmaceuticals has announced positive data from a Phase II trial evaluating RECCE 327 Topical Gel (R327G) ...

Recce Pharmaceuticals’ synthetic gel successfully treated a range of skin infections in a phase 2 trial, leading the ...

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 ...

The actinic keratosis treatment market is expected to grow from USD 6.13 billion in 2024 to USD 12.28 billion by 2034, at a CAGR of 7.2%. Increasing concerns over skin cancer and advancements in ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

The Phase II trial saw Recce 327 achieving all primary and secondary endpoints as the company looks to launch a Phase III ...

Recce Pharmaceuticals Ltd (ASX:RCE) has yielded positive data on the effectiveness of its topical gel in treating Acute ...